Breast cancer (invasive) · line 1 · Ribociclib adjuvant + AI (HR+/HER2- early breast cancer; NATALEE)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-RIBOCICLIB-AI-ADJUVANT |
| ID | IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-08 | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-NATALEE-SLAMON-2024 SRC-NCCN-BREAST-2025 |
Notes
STUB — pending Co-Lead sign-off. Brief specified year 2023 but PubMed fetch confirmed publication year 2024 (NEJM vol 390, pp 1080-1091, PMID 38507751); source ID and file use 2024. Key distinction from monarchE: NATALEE includes node-negative high-risk patients. Regimen REG-RIBOCICLIB-AI-ADJUVANT created alongside (400 mg adjuvant dose; separate from metastatic REG-AI-RIBOCICLIB at 600 mg). CI-PREGNANCY-TERATOGEN and congenital long QT CI entities do not yet exist; teratogenicity and QTc cutoff captured in do_not_do bullets instead.
Used By
Algorithms
ALGO-BREAST-1L- ALGO-BREAST-1L